Introduction
============

Liver cancer is one of the most common lethal cancers worldwide. It has been reported that liver cancer ranks sixth among the most commonly diagnosed cancers worldwide, and was the fourth major cause of cancer-related deaths in 2018. Global cancer statistics indicate that \~841,000 new cases and 782,000 deaths occur annually ([@b1-or-0-0-7224]). Hepatocellular carcinoma (HCC) is the major histological type of primary liver cancer, accounting for 75--85% of all cases. Infection with hepatitis virus \[mainly hepatitis B virus (HBV) and hepatitis C virus\], aflatoxin exposure, excessive alcohol consumption and tobacco smoking, are considered as the main risk factors for the development of HCC ([@b2-or-0-0-7224],[@b3-or-0-0-7224]). In China, the predominant cause of HCC is chronic HBV infection, and it is estimated that \~70% of these patients have an established HBV infection history ([@b4-or-0-0-7224]). Although the available therapies for HCC patients have greatly improved over the past decades, the clinical prognosis remains unfavorable, with a 5-year overall survival (OS) rate of \~30% following hepatic resection ([@b2-or-0-0-7224],[@b5-or-0-0-7224]). Therefore, it is imperative to identify more sensitive diagnostic and prognostic biomarkers for HCC.

Wingless-type MMTV integration site (*WNT*) genes are a family of 19 genes that modulate both the canonical WNT signal transduction pathway (referred to as β-catenin-dependent) and non-canonical WNT signal transduction pathway (referred to as β-catenin-independent) ([@b6-or-0-0-7224]). Previous studies indicated that *WNT* family genes are associated with various tumor biological processes, including cell proliferation ([@b7-or-0-0-7224],[@b8-or-0-0-7224]), invasion ([@b8-or-0-0-7224]--[@b11-or-0-0-7224]), metastasis ([@b12-or-0-0-7224],[@b13-or-0-0-7224]) and drug resistance ([@b13-or-0-0-7224]--[@b15-or-0-0-7224]). In addition, some researchers have reported that aberrant *WNT* expression levels are associated with diagnosis and prognosis prediction for certain tumors. Fu *et al* ([@b16-or-0-0-7224]) proved that *WNT2* can activate the WNT/β-catenin signal transduction pathway, which ultimately promotes esophageal cancer cell growth, and *WNT2* enhances cell motility and invasiveness by inducing epithelial-to-mesenchymal transition. Furthermore, *WNT2* expression level was found to be closely associated with the poor clinical performance status of patients with esophageal squamous cell carc *WNT* inoma.

However, the diagnostic and prognostic value of the *WNT* gene family expression in HBV-related HCC remains unclear. The primary goal of the present study was to investigate this association by collecting data from public databases and performing a series of bioinformatics analyses.

Materials and methods
=====================

### Data sources

The clinical characteristics of patients with HBV-related HCC and the corresponding *WNT* gene family expression levels were downloaded from the GSE14520 dataset of Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520>, accessed November 28, 2018) ([@b17-or-0-0-7224],[@b18-or-0-0-7224]). The detailed process of GSE14520 genome-wide expression profile dataset processing has been described in our previous article ([@b19-or-0-0-7224]). The Cancer Genome Atlas (TCGA) database HCC cohort was used as a validation cohort, and the data processing of RNA sequencing was described in our previous paper ([@b19-or-0-0-7224]). The raw RNA sequencing dataset of TCGA was normalized by DESeq ([@b20-or-0-0-7224]). The clinical data of these patients in the GSE14520 dataset included age, gender, serum alanine aminotransferase level, serum α-fetoprotein (AFP) level, cirrhosis, main tumor size, tumor number, Barcelona Clinic Liver Cancer (BCLC) stage, tumor-node-metastasis (TNM) stage, survival time, and survival status. The data for mRNA expression level of five *WNT* family genes (*WNT3A, WNT8A, WNT9A, WNT9B* and *WNT10A*) were unavailable in the Gene Expression Omnibus (GEO) database. Therefore, only 14 *WNT* genes were finally analyzed in the present study. As the dataset included in our research was obtained from a public database, the study did not require the approval of an ethics committee.

### Bioinformatics analysis of WNT family genes

To explore the potential biological functions and possible pathways of *WNT* family genes, gene enrichment analyses, including Gene Ontology (GO) functional analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, were conducted by applying the Database for Annotation, Visualization, and Integrated Discovery (DAVID) bioinformatics online tool, version 6.8 (<https://david.ncifcrf.gov/>, accessed December 2, 2018) ([@b21-or-0-0-7224]). Statistically, an enrichment P-value of \<0.05 was considered to indicate statistically significant differences. In order to further validate the results of enrichment analysis by DAVID, application package Biological Networks Gene Ontology tool (BiNGO) in the Cytoscape software (version 3.7.1) ([@b22-or-0-0-7224]) was used to explore the GO terms of *WNT* family genes. Pearson\'s correlation coefficient was calculated to assess the relevance among *WNT* genes in the co-expression analysis. These data were visualized by the correlation plot package in the R platform (version 3.4.0). *WNT* gene-gene and protein-protein interactions were investigated by using the online resource GeneMANIA (<http://genemania.org/>, accessed December 6, 2018) ([@b23-or-0-0-7224]) and the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) (<https://string-db.org/cgi/input.pl>, accessed December 6, 2018) ([@b24-or-0-0-7224],[@b25-or-0-0-7224]), respectively.

### Assessment of diagnostic value

The expression level of *WNT* family genes in tumor tissues and corresponding adjacent non-tumor tissues were compared via t-test statistical analysis. The public online resource Metabolic gEne RApid Visualizer (MERAV) (<http://merav.wi.mit.edu/>, accessed December 8, 2018) ([@b26-or-0-0-7224]) was used to further validate that genes of the *WNT* family were differentially expressed between primary liver cancer tissues and normal liver tissues. Receiver operating characteristic (ROC) curve analysis was selected to determine the diagnostic value of these differentially expressed *WNT* family genes.

### Survival analysis

The 212 patients with HBV-related HCC were categorized into high- and low-expression groups based on the median *WNT* gene expression level in tumor tissues. In order to investigate whether the expression level of *WNT* family genes was correlated with prognosis and outcome, Cox proportional hazard regression analysis and Kaplan-Meier survival analysis with log-rank tests were used to evaluate the association between *WNT* family gene expression, OS and recurrence-free survival (RFS).

### Joint effects analysis of WNT family genes

Based on the results of multivariate Cox proportional hazard regression analysis and Kaplan-Meier survival analysis, only *WNT1* and *WNT6* were found to be significantly associated with RFS. Therefore, the combined effects of *WNT1* and *WNT6* were analyzed. The combinations were as follows: Low *WNT1* expression and low *WNT6* expression (group 1), low *WNT1* expression and high *WNT6* expression (group 2), high *WNT1* expression and low *WNT6* expression (group 3), and high *WNT1* expression and high *WNT6* expression (group 4).

### Prognostic nomogram for survival prediction

All 212 patients with HBV-related HCC in the GSE14520 dataset of the GEO database were identified as the source population for nomogram construction. The variables that were related to prognosis outcome were selected to construct the nomogram, including sex, serum AFP level, cirrhosis, BCLC stage, tumor size and *WNT* gene expression. With each variable being assigned a score, the total point was calculated by summing up the scores of all the variables and located onto the scale. Therefore, the probabilities of the survival outcome could be predicted by drawing a vertical line to the total point.

### Statistical analysis

All statistical analyses were performed with the SPSS software package, version 17.0 (SPSS Inc.). Comparison of *WNT* family gene expression levels between tumor tissues and corresponding adjacent non-tumor tissues was performed using t-tests. The Cox proportional hazards regression model was selected for univariate and multivariate analyses. By applying Kaplan-Meier survival analysis with log-rank test, the association of *WNT* family gene expression levels with OS and RFS time was observed. Vertical scatter plots, ROC curves and survival curves were plotted by GraphPad Prism software, version 7.0 (GraphPad Software, Inc.). P\<0.05 was considered to indicate statistically significant differences.

Results
=======

### Characteristics of patients in the GEO database

In the GSE14520 dataset of the GEO database, there remained 212 patients with HBV-related HCC after excluding patients who had no reported HBV infection or any available survival information. Detailed characteristics of these patients are shown in [Table SI](#SD1-or-0-0-7224){ref-type="supplementary-material"}. Serum AFP level, cirrhosis, tumor size, BCLC stage and TNM stage were found to be closely associated with OS (P\<0.05), whereas sex, cirrhosis, BCLC stage and TNM stage were significantly associated with RFS (P\<0.05). The remaining characteristics did not exhibit a significant association with OS or RFS (all P\>0.05).

### Bioinformatics analysis of WNT family genes

The GO function analysis indicated that *WNT* family genes were mainly enriched in the regulation of cell differentiation, cell proliferation, epithelial-to-mesenchymal transition, and modulation of the WNT signaling pathway ([Figs. 1A](#f1-or-0-0-7224){ref-type="fig"}, [S1](#SD1-or-0-0-7224){ref-type="supplementary-material"} and [S2](#SD1-or-0-0-7224){ref-type="supplementary-material"}, and [Table SII](#SD1-or-0-0-7224){ref-type="supplementary-material"}). The KEGG pathway analysis suggested that *WNT* family genes were associated with the WNT signaling pathway and other pathways ([Fig. 1B](#f1-or-0-0-7224){ref-type="fig"} and [Table SIII](#SD1-or-0-0-7224){ref-type="supplementary-material"}). The Pearson\'s correlation coefficients of *WNT* family genes were calculated and used to assess whether these genes were correlated with each other. As shown in [Fig. 2](#f2-or-0-0-7224){ref-type="fig"}, the *WNT* family genes were correlated to some degree. The gene-gene and protein-protein interaction networks constructed by GeneMANIA and STRING, respectively, indicated that the *WNT* family genes were co-expressed and exhibited extensive homology at the protein level ([Fig. 3A and B](#f3-or-0-0-7224){ref-type="fig"}).

### Assessment of diagnostic value

By comparing *WNT* family gene expression levels between tumor tissues and corresponding adjacent non-tumor tissues, a total of 8 *WNT* family genes (*WNT2, WNT2B, WNT4, WNT5A, WNT7B, WNT10B, WNT11* and *WNT16*) were found to be differentially expressed in tumor and non-tumor tissues ([Fig. 4](#f4-or-0-0-7224){ref-type="fig"}) (P\<0.05). The online resource MERAV was used to further validate genes of the *WNT* family that were differentially expressed in normal liver tissues and primary liver cancer tissues ([Fig. 5](#f5-or-0-0-7224){ref-type="fig"}). An ROC curve was constructed to further explore the diagnostic value of these 8 differentially expressed genes. As shown in [Fig. 6](#f6-or-0-0-7224){ref-type="fig"}, six *WNT* genes (*WNT2, WNT2B, WNT5A, WNT10B, WNT11* and *WNT16*) had a potential prediction value, with all P-values \<0.05 and area under the curve (AUC) \>0.500; *WNT2* in particular exhibited high accuracy in differentiating HCC tissues from non-tumor tissue (P\<0.0001, AUC=0.810, 95% CI: 0.767--0.852).

### Survival analysis

The characteristics associated with clinical prognostic outcome, including cirrhosis, tumor size and BCLC stage, were included in the multivariate Cox regression analysis. Following adjustment or these prognosis-related risk factors, the results indicated that the expression level of *WNT1* was significantly associated with OS and RFS in the survival analysis (adjusted P=0.033, adjusted HR=0.607, 95% CI: 0.384--0.960 and adjusted P=0.007, adjusted HR=0.592, 95% CI: 0.404--0.868, respectively) ([Table I](#tI-or-0-0-7224){ref-type="table"}; [Figs. 7A](#f7-or-0-0-7224){ref-type="fig"} and [8A](#f8-or-0-0-7224){ref-type="fig"}). The expression level of *WNT6* was closely associated with RFS (adjusted P=0.033, adjusted HR=0.665, 95% CI: 0.457--0.968), but *WNT6* did not exhibit a significant association with OS (P\>0.05) ([Table I](#tI-or-0-0-7224){ref-type="table"}; [Figs. 7H](#f7-or-0-0-7224){ref-type="fig"} and [8H](#f8-or-0-0-7224){ref-type="fig"}).

### Joint effects analysis of WNT family genes

As shown above, the multivariate Cox regression analysis and Kaplan-Meier survival analysis demonstrated that only *WNT1* and *WNT6* were significantly associated with RFS. Joint effects survival analysis for *WNT1* and *WNT6* was performed following adjustment for cirrhosis, tumor size and BCLC stage. The results suggested that group 4 (high *WNT1* expression and high *WNT6* expression) had the longest RFS, whereas group 1 (low *WNT1* expression and low *WNT6* expression) had the shortest RFS ([Table II](#tII-or-0-0-7224){ref-type="table"} and [Fig. 9](#f9-or-0-0-7224){ref-type="fig"}). Therefore, patients with a high expression of both *WNT1* and *WNT6* are expected to have a longer RFS.

### Prognostic nomogram for survival prediction

The prognostic risk factors that may predict the outcome of survival, including sex, serum AFP level, cirrhosis, BCLC stage, tumor size and *WNT* family gene expression, were selected to construct the nomogram, which can provide an individualized prognosis prediction. For the 212 patients with HBV-related HCC, nomogram analysis was performed for the probabilities of 1-, 2-, 3-, 4- and 5-year OS ([Fig. 10A](#f10-or-0-0-7224){ref-type="fig"}) and RFS ([Fig. 10B](#f10-or-0-0-7224){ref-type="fig"}). As shown in the nomogram, the expression level of *WNT1* and *WNT6* contributed to a certain extent to the patients\' clinical prognosis outcome.

### TCGA validation cohort

A total of 374 tumor tissues and 50 adjacent non-tumor tissues were included in the present study. Among those, 370 HCC patients with prognostic information were included in the survival analysis. The expression distribution of the *WNT* family genes between HCC tumor tissues and adjacent non-tumor tissues were calculated by DESeq and are shown in [Table III](#tIII-or-0-0-7224){ref-type="table"}. *WNT2* was shown to be significantly differentially expressed between HCC and adjacent non-tumor tissues in the TCGA cohort ([Table III](#tIII-or-0-0-7224){ref-type="table"}, [Fig. 11A and B](#f11-or-0-0-7224){ref-type="fig"}). The clinical characteristics of HCC patients in the TCGA cohort are shown in [Table SIV](#SD1-or-0-0-7224){ref-type="supplementary-material"}. The survival analysis results of the *WNT* family genes are shown in [Table IV](#tIV-or-0-0-7224){ref-type="table"}. *WNT*1 was found to be associated with both the OS and RFS of HCC in the TCGA cohort ([Table IV](#tIV-or-0-0-7224){ref-type="table"}, [Fig. 11C and D](#f11-or-0-0-7224){ref-type="fig"}).

Discussion
==========

The aim of the present study was to investigate the diagnostic and prognostic values of *WNT* family gene expression in HBV-related HCC established on public databases and a series of bioinformatics analyses. The results suggested that *WNT2* may serve as potential diagnostic biomarker for HBV-related HCC. In addition, we demonstrated that the expression level of *WNT1* was significantly associated with clinical prognostic outcome, with patients with a higher expression level of *WNT1* expected to have a better prognostic outcome. Therefore, it may be concluded that *WNT1* may serve as potential prognostic biomarker for patients with HBV-related HCC.

Previous studies confirmed that the WNT signaling pathway plays a crucial role in numerous physiological and pathological processes, including the regeneration of hair and skin ([@b27-or-0-0-7224]), the repair of liver and lung after injury ([@b28-or-0-0-7224],[@b29-or-0-0-7224]), hematopoiesis ([@b30-or-0-0-7224],[@b31-or-0-0-7224]) and neurogenesis ([@b32-or-0-0-7224]). Furthermore, other studies have demonstrated that the aberrant regulation of WNT signaling may contribute to various diseases, including cancer ([@b6-or-0-0-7224],[@b33-or-0-0-7224]--[@b35-or-0-0-7224]), osteoporosis ([@b36-or-0-0-7224],[@b37-or-0-0-7224]), fibrosis ([@b38-or-0-0-7224]--[@b40-or-0-0-7224]), autoimmune diseases ([@b41-or-0-0-7224]--[@b43-or-0-0-7224]), neurological diseases ([@b44-or-0-0-7224],[@b45-or-0-0-7224]), and disorders of endocrine function ([@b46-or-0-0-7224]--[@b48-or-0-0-7224]). The WNT signaling pathway has been shown to either promote or inhibit cancer biological progression in a cancer stage- and type-specific manner ([@b6-or-0-0-7224]). *WNT* family genes, as the most important component of the WNT signaling pathway, participate in the initiation and progression of various cancers, such as esophageal carcinoma ([@b16-or-0-0-7224]), gastric cancer ([@b49-or-0-0-7224]), pancreatic cancer ([@b50-or-0-0-7224]), prostate cancer ([@b51-or-0-0-7224]), ovarian cancer ([@b52-or-0-0-7224],[@b53-or-0-0-7224]), and leukemia ([@b54-or-0-0-7224]). Numerous studies have reported that *WNT* family genes may regulate cell proliferation ([@b50-or-0-0-7224],[@b54-or-0-0-7224]), differentiation, epithelial-to-mesenchymal transition ([@b7-or-0-0-7224],[@b12-or-0-0-7224]) and WNT signaling ([@b9-or-0-0-7224],[@b16-or-0-0-7224]). The conclusions of those studies were consistent with the results of gene function enrichment analysis in DAVID.

Early discoveries confirmed that *WNT* family genes may serve as potential diagnostic biomarkers for certain types of cancer. Sin *et al* selected RNA sequencing as a discovery method for specific RNA markers in bladder cancer, and found that *WNT5A* detection was a valuable complementary strategy in cystoscopy that may reduce unnecessary diagnostic procedures for bladder cancer ([@b55-or-0-0-7224]). Jiang *et al* had reported that *WNT6* may serve as a diagnostic biomarker for osteosarcoma, with an AUC of 0.854, a specificity of 88.4% and a sensitivity of 77.8% ([@b56-or-0-0-7224]). Based on these previous studies, it may be hypothesized that *WNTs* may also predict HCC. To test this hypothesis and evaluate the diagnostic value of *WNT* genes, an ROC curve was constructed, and the analysis suggested that *WNT2* may serve as potential diagnostic biomarker for patients with HBV-related HCC.

In addition, we also investigated the prognostic prediction ability of *WNT* family genes. The results demonstrated that the expression level of *WNT1* was associated with OS and RFS, with patients exhibiting a higher expression level of *WNT1* having a better prognostic outcome. Therefore, *WNT1* may serve as potential prognostic biomarker for HBV-related HCC. It has been reported that *WNT* family genes may predict the prognostic outcome in several types of cancer. As previously reported, *WNT1* expression may be one of the mechanisms underlying WNT/β-catenin signaling pathway activation in non-small cell lung cancer, and aberrant *WNT1* expression level was found to be a predictor of adverse prognosis ([@b57-or-0-0-7224]). Shi *et al* reported that the *WNT2B* genetic variant may be a biomarker for the outcome of patients with cutaneous melanoma ([@b58-or-0-0-7224]). Jiang *et al* observed that high expression of *WNT6* was a predictor of poor survival of osteosarcoma ([@b56-or-0-0-7224]). Numerous studies have demonstrated that the expression level of *WNT5A* is associated with prognostic outcome and may serve as a prognostic biomarker in hepatocellular carcinoma ([@b59-or-0-0-7224]), gallbladder carcinoma ([@b60-or-0-0-7224]) and medulloblastoma ([@b61-or-0-0-7224]). Based on these early discoveries, a prognostic predictive function for *WNT* family genes in HBV-related HCC has been confirmed in the present study.

We herein explored the diagnostic and prognostic value of *WNT* family gene expression in HBV-related HCC by collecting data from public databases and performing a series of bioinformatics analyses, with the aim of identifying more sensitive biomarkers and design a novel strategy for HCC diagnosis and treatment. There were certain limitations to the present study that must be addressed. First, the data were obtained from a public database and the sample size was limited; therefore, a larger population and multi-centered clinical studies are required to increase the credibility of our conclusions. Second, complete clinical parameters must be included to better evaluate the association between *WNT* family genes and HCC prognosis. Third, further functional validation and clinical trials are required to reveal the underlying molecular mechanism. Finally, although we explored the diagnostic and prognostic value at the mRNA level, the protein level was not investigated in the present study. Therefore, a comprehensive research design is required to check the consistency between mRNA and protein expression.

In conclusion, the findings of the present study demonstrated that *WNT2* may serve as diagnostic biomarker and *WNT1* may serve as prognostic biomarker for patients with HBV-related HCC in the GSE14520 cohort. Furthermore, through verification of the TCGA cohort, the diagnostic value of *WNT2* and the prognostic value of *WNT1* may be further validated and generalized to HCC patients. Therefore, our results require further confirmation.

Supplementary Material
======================

###### Supporting Data

The authors would like to acknowledge the laboratory equipment and platform support sponsored by the Key Laboratory of Early Prevention and Treatment for Regional High-Incidence Tumors (Guangxi Medical University; Ministry of Education, Nanning, China). The authors would also like to acknowledge the helpful comments on this article received from our reviewers. In addition, we would also like to thank the contributors of GSE14520 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520>) and The Cancer Genome Atlas (<https://cancergenome.nih.gov/>).

Funding
=======

The present study was sponsored in part by the 2018 Innovation Project of Guangxi Graduate Education (grant nos. JGY2018037 and YCBZ2018036), the Guangxi Key Laboratory for the Prevention and Control of Viral Hepatitis (grant no. GXCDCKL201902), the National Natural Science Foundation of China (grant no. 81802874), the Natural Science Foundation of the Guangxi Province of China (grant no. 2018GXNSFBA138013), the Key laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education (grant no. GKE2018-01), and the Guangxi Key R & D Program (grant no. GKEAB18221019).

Availability of data and materials
==================================

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Authors\' contributions
=======================

QH and XY designed this study. XW, XL, CH, TY, CY, GL, BH, KH, GZ, ZL, XZ, HS, LS, YG, XS, TP and XY conducted this study and analyzed the data. QH wrote the manuscript and XY revised the manuscript. All the authors have read and approved the final version of the manuscript for publication and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate
==========================================

Not applicable.

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.
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![Expression levels of *WNT* family genes in normal liver and primary liver cancer tissues, as analyzed by MERAV.](or-42-03-0895-g04){#f5-or-0-0-7224}

###### 

The receiver operating characteristics (ROC) curves of *WNT* family genes in distinguish HBV-related HCC tumor tissues and adjacent non-tumor tissues in GES14520. ROC curves of (A) *WNT2*; (B) *WNT2B*; (C) *WNT4*; (D) *WNT5A*; (E) *WNT7B*; (F) *WNT10B*; (G) *WNT11*; and (H) *WNT16*. AUC, area under the ROC curve; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.
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![Kaplan-Meier survival curves for *WNT* genes in HBV-related HCC of GES14520. OS stratified by (A) *WNT1*; (B) *WNT2*; (C) *WNT2B*; (D) *WNT3*; (E) *WNT4*; (F) *WNT5A*; (G) *WNT5B*; (H) *WNT6*; (I) *WNT7A*; (J) *WNT7B*; (K) *WNT8B*; (L) *WNT10B*; (M) *WNT11*; and (N) *WNT16*. HBV, hepatitis B virus; HCC, hepatocellular carcinoma; OS, overall survival.](or-42-03-0895-g07){#f7-or-0-0-7224}

![Kaplan-Meier survival curves for *WNT* genes in HBV-related HCC of GES14520. RFS stratified by (A) *WNT1*; (B) *WNT2*; (C) *WNT2B*; (D) *WNT3*; (E) *WNT4*; (F) *WNT5A*; (G) *WNT5B*; (H) *WNT6*; (I) *WNT7A*; (J) *WNT7B*; (K) *WNT8B*; (L) *WNT10B*; (M) *WNT11*; and (N) *WNT16*. HBV, hepatitis B virus; HCC, hepatocellular carcinoma; RFS, recurrence-free survival.](or-42-03-0895-g08){#f8-or-0-0-7224}

![Joint effects analysis for the combination of *WNT1* and *WNT6*.](or-42-03-0895-g09){#f9-or-0-0-7224}

![Prognostic nomogram for survival prediction. (A) Nomogram for overall survival; (B) nomogram for recurrence-free survival. AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer.](or-42-03-0895-g10){#f10-or-0-0-7224}

![Diagnostic and prognostic values of *WNT* genes in TCGA validation cohort. (A) the relative expression of *WNT2* in HCC tumor tissues and non-tumor tissues; (B) ROC curves of *WNT2*; (C) Kaplan-Meier survival curves of *WNT1* for OS; (D) Kaplan-Meier survival curves of *WNT1* for RFS. TCGA, The Cancer Genome Atlas; HCC, hepatocellular carcinoma; ROC, receiver operating characteristics; AUC, area under the ROC curve; OS, overall survival; RFS, recurrence-free survival.](or-42-03-0895-g11){#f11-or-0-0-7224}

###### 

Prognostic values of *WNT* gene expression in HBV-related HCC of the GSE14520 cohort.

                   OS   RFS                                                                                                              
  ---------- ----- ---- ----- ---------------- ------- ----------------- ----------- ---- ---- ---------------- ------- ---------------- -----------
  *WNT1*                                                                                                                                 **0.007**
    Low      106   49   NA    1                        1                             66   27   1                        1                
    High     106   33   NA    0.575            0.014   0.607             **0.033**   50   57   0.588            0.005   0.592            
                              (0.370--0.895)           (0.384--0.960)                          (0.406--0.850)           (0.404--0.868)   
  *WNT2*                                                                                                                                 0.444
    Low      106   43   NA    1                        1                             58   40   1                        1                
    High     106   39   NA    0.872            0.534   0.784             0.282       58   46   0.935            0.718   0.865            
                              (0.565--1.345)           (0.503--1.222)                          (0.650--1.346)           (0.597--1.254)   
  *WNT2B*                                                                                                                                0.091
    Low      106   38   NA    1                        1                             54   46   1                        1                
    High     106   44   NA    1.178            0.461   1.344             0.192       62   37   1.215            0.295   1.378            
                              (0.763--1.818)           (0.862--2.093)                          (0.844--1.751)           (0.950--1.997)   
  *WNT3*                                                                                                                                 0.622
    Low      106   37   NA    1                        1                             56   51   1                        1                
    High     106   45   NA    1.306            0.230   1.279             0.285       60   41   1.116            0.556   1.099            
                              (0.845--2.018)           (0.814--2.008)                          (0.775--1.606)           (0.754--1.601)   
  *WNT4*                                                                                                                                 0.113
    Low      106   39   NA    1                        1                             63   35   1                        1                
    High     106   43   NA    1.229            0.352   1.116             0.624       53   53   0.828            0.313   0.742            
                              (0.796--1.896)           (0.720--1.730)                          (0.575--1.194)           (0.512--1.074)   
  *WNT5A*                                                                                                                                0.663
    Low      106   45   NA    1                        1                             62   36   1                        1                
    High     106   37   NA    0.847            0.456   0.915             0.690       54   51   0.875            0.473   0.922            
                              (0.549--1.309)           (0.591--1.417)                          (0.607--1.260)           (0.638--1.331)   
  *WNT5B*                                                                                                                                0.641
    Low      106   40   NA    1                        1                             64   46   1                        1                
    High     106   42   NA    1.068            0.766   1.328             0.215       52   43   0.803            0.240   0.915            
                              (0.693--1.647)           (0.848--2.078)                          (0.557--1.158)           (0.630--1.329)   
  *WNT6*                                                                                                                                 **0.033**
    Low      106   48   60    1                        1                             66   30   1                        1                
    High     106   34   NA    0.662            0.066   0.756             0.222       50   57   0.644            0.019   0.665            
                              (0.426--1.027)           (0.483--1.184)                          (0.446--0.931)           (0.457--0.968)   
  *WNT7A*                                                                                                                                0.180
    Low      106   43   NA    1                        1                             62   41   1                        1                
    High     106   39   NA    0.776            0.253   0.764             0.229       54   48   0.757            0.136   0.778            
                              (0.503--1.198)           (0.492--1.185)                          (0.526--1.091)           (0.539--1.123)   
  *WNT7B*                                                                                                                                0.522
    Low      106   36   NA    1                        1                             53   54   1                        1                
    High     106   46   60    1.421            0.115   1.057             0.812       63   30   1.390            0.078   1.132            
                              (0.918--2.200)           (0.670--1.667)                          (0.963--2.004)           (0.775--1.655)   
  *WNT8B*                                                                                                                                0.721
    Low      106   38   NA    1                        1                             57   48   1                        1                
    High     106   44   NA    1.192            0.428   0.904             0.654       59   37   1.103            0.597   0.935            
                              (0.772--1.840)           (0.580--1.407)                          (0.766--1.588)           (0.646--1.354)   
  *WNT10B*                                                                                                                               0.079
    Low      106   46   60    1                        1                             64   30   1                        1                
    High     106   36   NA    0.704            0.115   0.691             0.101       52   57   0.703            0.060   0.717            
                              (0.455--1.090)           (0.445--1.0750)                         (0.487--1.014)           (0.495--1.039)   
  *WNT11*                                                                                                                                0.371
    Low      106   47   60    1                        1                             63   35   1                        1                
    High     106   35   NA    0.685            0.090   0.740             0.186       53   54   0.744            0.113   0.843            
                              (0.442--1.061)           (0.474--1.156)                          (0.515--1.073)           (0.581--1.225)   
  *WNT16*                                                                                                                                0.349
    Low      106   40   NA    1                        1                             60   37   1                        1                
    High     106   42   NA    0.974            0.906   0.950             0.819       56   46   0.835            0.332   0.838            
                              (0.632--1.503)           (0.611--1.477)                          (0.580--1.202)           (0.580--1.212)   

Adjusted for cirrhosis, tumor size and BCLC stage. Bold print indicates statistical significance. HBV, hepatitis B virus; HCC, hepatocellular carcinoma; OS, overall survival; RFS, recurrence-free survival; MST, median survival time; MRT, median recurrence time; HR, hazard ratio; CI, confidence interval; NA, not available; BCLC, Barcelona Clinic Liver Cancer.

###### 

Joint effects analysis for the combination of *WNT1* and *WNT6*.

  Group   *WNT1* expression   *WNT6* expression   Patients (n=212)   MRT (months)   Crude HR (95% CI)      Crude P-value   Adjusted HR (95% CI)   Adjusted P-value^[a](#tfn2-or-0-0-7224){ref-type="table-fn"}^
  ------- ------------------- ------------------- ------------------ -------------- ---------------------- --------------- ---------------------- ---------------------------------------------------------------
  1       Low                 Low                 56                 18             NA                     0.001           NA                     P\<0.001
  2       Low                 High                50                 49             0.524 (0.318--0.862)   0.011           0.457 (0.276--0.755)   0.002
  3       High                Low                 50                 51             0.478 (0.290--0.787)   0.004           0.413 (0.250--0.683)   0.001
  4       High                High                56                 NA             0.401 (0.243--0.662)   P\<0.001        0.405 (0.240--0.684)   0.001

Adjusted for cirrhosis, tumor size and BCLC stage. MRT, median recurrence time; HR, hazard ratio; CI, confidence interval; NA, not available; BCLC, Barcelona Clinic Liver Cancer.

###### 

Expression distribution of *WNT* family genes between tumor tissue and adjacent non-tumor tissue in the TCGA validation cohort.

  Gene       Log~2~ (fold change)   P-value       FDR
  ---------- ---------------------- ------------- -------------
  *WNT1*     1.84421242             0.946083391   0.999996922
  *WNT2*     −1.769264955           0.002852902   0.022026272
  *WNT2B*    1.360412766            0.373384363   0.65436372
  *WNT3*     0.066523683            0.810682922   0.928938592
  *WNT4*     1.309792732            0.026270116   0.120328643
  *WNT5A*    0.650962704            0.073901092   0.249424709
  *WNT5B*    −0.101243468           0.644473376   0.842930166
  *WNT6*     2.792018889            0.42971413    0.703074675
  *WNT7A*    0.13572947             1             1
  *WNT7B*    1.071320247            0.324934599   0.610626696
  *WNT8B*    1.918325871            0.070391904   0.241649148
  *WNT10B*   1.121445938            0.298549628   0.582917358
  *WNT11*    −1.50622528            0.000105087   0.001433939
  *WNT16*    −0.077860553           0.822321775   0.934493001

TCGA, The Cancer Genome Atlas; FDR, false discovery rate.

###### 

Survival analysis results of the *WNT* family genes in the TCGA validation cohort.

             RFS        OS                                                                              
  ---------- ---------- ------------ ------------ ------------ ------------- ------------ ------------- -------------
  *WNT1*     0.004872   0.5585569    0.37237755   0.83782122   0.038128301   0.67054664   0.459578646   0.978358776
  *WNT2*     0.165437   0.74242449   0.48738676   1.13091729   0.463552265   1.15543359   0.78518841    1.700262972
  *WNT2B*    0.172666   0.75604408   0.5058112    1.13007116   0.949318195   0.9878679    0.678014074   1.439325557
  *WNT3*     0.111201   1.39315603   0.92641981   2.09503695   0.23053025    0.7955497    0.547382364   1.156228935
  *WNT4*     0.038296   0.65324005   0.43663377   0.97730085   0.308986119   0.82048053   0.560425379   1.201209516
  *WNT5A*    0.25247    0.79158048   0.53045358   1.18125258   0.823749524   0.95871339   0.661532981   1.389396128
  *WNT5B*    0.421213   0.84734859   0.56593122   1.26870474   0.701474468   0.92888443   0.637015977   1.354481386
  *WNT6*     0.571806   0.88958796   0.5929931    1.33452943   0.640628505   1.09289911   0.752662101   1.586938493
  *WNT7A*    0.000396   0.47050498   0.31004378   0.71401184   0.668569853   0.92232626   0.636972232   1.335514626
  *WNT7B*    0.156162   0.73979971   0.4877709    1.12205056   0.874887781   1.0304464    0.709391742   1.496803142
  *WNT8B*    0.36875    0.83403019   0.56144901   1.23894839   0.230696394   0.79551932   0.547254355   1.156411068
  *WNT10B*   0.052198   0.6701836    0.44743955   1.00381395   0.23391077    0.79061532   0.536982043   1.16404746
  *WNT11*    0.012024   0.59538341   0.397232     0.89237879   0.084433724   0.71556062   0.489264738   1.046523402
  *WNT16*    0.039333   0.65216604   0.43430059   0.97932296   0.457153569   1.15299749   0.792227421   1.678057559

TCGA, The Cancer Genome Atlas; RFS, recurrence-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.
